References
- Alimujiang S, Zhang T, Han ZG, et al. (2013) Epidermal growth factor receptor tyrosine kinase inhibitor versus placebo as maintenance therapy for advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev, 14, 2413-9. https://doi.org/10.7314/APJCP.2013.14.4.2413
- Camidge DR. (2013) Icotinib: kick-starting the Chinese anticancer drug industry. Lancet Oncol, 14, 913-4. https://doi.org/10.1016/S1470-2045(13)70385-1
- Gao Z, Chen W, Zhang X, et al. (2013) Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling. Biomed Pharmacother, 67, 351-6. https://doi.org/10.1016/j.biopha.2013.03.012
- Hirsch FR, Varella-Garcia M, Bunn PA, et al. (2006) Molecular predictors of outcome with gefitinib in a phase III placebocontrolled study in advanced non-small-cell lung cancer. J Clin Oncol, 24, 5034-42. https://doi.org/10.1200/JCO.2006.06.3958
- Liam CK, Leow HR, How SH, et al. (2014) Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic Malaysian patient population. Asian Pac J Cancer Prev, 15, 321-6. https://doi.org/10.7314/APJCP.2014.15.1.321
- Liu D, Jiang J, Zhang L, et al. (2011) Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom, 25, 2131-40. https://doi.org/10.1002/rcm.5061
- Liu D, Jiang J, Zhang L, et al. (2014) Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects. Cancer Chemother Pharmacol, (in press).
- Mu X, Zhang Y, Qu X, et al. (2013) Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer. Biomed Res Int, 2013, 726375.
- Pan JB, Hou YH, Zhang GJ. (2013) Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients. Asian Pac J Cancer Prev, 14, 695-700. https://doi.org/10.7314/APJCP.2013.14.2.695
- Qi WX, Shen Z, Lin F, et al. (2012) Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 13, 5177-82. https://doi.org/10.7314/APJCP.2012.13.10.5177
- Ruan CJ, Liu DY, Jiang J, et al. (2012) Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers. Eur J Clin Pharmacol, 68, 1677-80. https://doi.org/10.1007/s00228-012-1288-4
- Shao L, Zhang B, He C, et al. (2014) Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy. Chin Med J, 127, 266-71.
- Shi Y, Zhang L, Liu X, et al. (2013) Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 noninferiority trial. Lancet Oncol, 14, 953-61. https://doi.org/10.1016/S1470-2045(13)70355-3
- Song Z, Yu X, Cai J, et al. (2013) [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified]. Zhongguo Fei Ai Za Zhi, 16, 138-43.
- Takano T, Fukui T, Ohe Y, et al. (2008) EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol, 26, 5589-95. https://doi.org/10.1200/JCO.2008.16.7254
- Tan F, Shen X, Wang D, et al. (2012) Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer, 76, 177-82. https://doi.org/10.1016/j.lungcan.2011.10.023
- Usuda K, Sagawa M, Motono N, et al. (2014) Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive? Asian Pac J Cancer Prev, 15, 657-62. https://doi.org/10.7314/APJCP.2014.15.2.657
- Wang HP, Zhang L, Wang YX, et al. (2011) Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer. Chin Med J, 124, 1933.
- Zhao Q, Shentu J, Xu N, et al. (2011) Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer, 73, 195-202. https://doi.org/10.1016/j.lungcan.2010.11.007
Cited by
- Effects of the CYP2C19 Genetic Polymorphism on Gastritis, Peptic Ulcer Disease, Peptic Ulcer Bleeding and Gastric Cancer vol.15, pp.24, 2014, https://doi.org/10.7314/APJCP.2014.15.24.10957
- Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib vol.7, pp.6, 2016, https://doi.org/10.1111/1759-7714.12380
- In Vivo Toxicity of Solasonine and Its Effects on cyp450 Family Gene Expression in the Livers of Male Mice from Four Strains vol.10, pp.12, 2018, https://doi.org/10.3390/toxins10120487